These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 26856453)
1. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Scheen AJ Diabetes Metab; 2016 Apr; 42(2):71-6. PubMed ID: 26856453 [No Abstract] [Full Text] [Related]
2. The EMPA-REG study: What has it told us? A diabetologist's perspective. DeFronzo RA J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076 [No Abstract] [Full Text] [Related]
5. Understanding EMPA-REG OUTCOME. Muskiet MH; van Raalte DH; van Bommel EJ; Smits MM; Tonneijck L Lancet Diabetes Endocrinol; 2015 Dec; 3(12):928-9. PubMed ID: 26590679 [No Abstract] [Full Text] [Related]
6. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Perreault L Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185 [TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER]. Scheen AJ; Piérard L; Krzesinski JM; Paquot N Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832 [TBL] [Abstract][Full Text] [Related]
9. Asian Perspective of the EMPA-REG OUTCOME Study. Bando YK; Murohara T Circ J; 2017 Jan; 81(2):155-157. PubMed ID: 28111376 [No Abstract] [Full Text] [Related]
10. London buses: A cardiovascular outcome trial equivalent? Grant PJ Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327 [No Abstract] [Full Text] [Related]
12. Absolute benefits of empagliflozin in type 2 diabetes: a game changer? Kumana CR; Tan KCB; Cheung BMY Postgrad Med J; 2017 Jul; 93(1101):373-375. PubMed ID: 28433975 [No Abstract] [Full Text] [Related]
13. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. Scheen AJ Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329 [TBL] [Abstract][Full Text] [Related]
14. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426 [TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER]. Scheen AJ; Wallemacq C; Jandrain B; Ernest P Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791 [TBL] [Abstract][Full Text] [Related]
17. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Perreault L Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344 [TBL] [Abstract][Full Text] [Related]
18. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]. Scheen AJ Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271 [TBL] [Abstract][Full Text] [Related]
19. Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. Alzaid A Diabetes Technol Ther; 2017 Jun; 19(6):324-327. PubMed ID: 28300428 [TBL] [Abstract][Full Text] [Related]
20. EMPA-REG OUTCOME: The Cardiologist's Point of View. Pham SV; Chilton R Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]